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Abstract
In most countries, surprisingly little is known on how national healthcare spending is distributed across diseases. Single-
disease cost-of-illness studies cover only a few of the diseases affecting a population and in some cases lead to untenably large 
estimates. The objective of this study was to decompose healthcare spending in 2011, according to Swiss National Health 
Accounts, into 21 collectively exhaustive and mutually exclusive major disease categories. Diseases were classified following 
the Global Burden of Disease Study. We first assigned the expenditures directly mapping from National Health Accounts 
to the 21 diseases. The remaining expenditures were assigned based on diagnostic codes and clues contained in a variety 
of microdata sources. Expenditures were dominated by non-communicable diseases with a share of 79.4%. Cardiovascular 
diseases stood out with 15.6% of total spending, followed by musculoskeletal disorders (13.4%), and mental and substance 
use disorders (10.6%). Neoplasms (6.0% of the total) ranked only sixth, although they are the leading cause of premature 
death in Switzerland. These results may be useful for the design of health policies, as they illustrate how healthcare spend-
ing is influenced by the epidemiological transition and increasing life expectancy. They also provide a plausibility check 
for single cost-of-illness studies. Our study may serve as a starting point for further research on the drivers of the constant 
growth of healthcare spending.
Keywords Healthcare expenditures · Cost-of-illness · Healthcare costs · National Health Accounts · Switzerland · 
Decomposition by diseases
JEL Classification I10 Health General · I11 Analysis of Health Care Markets
Introduction
Although it is quite well known how healthcare spending is 
financed and what kind of services are bought, surprisingly 
little is known on how much is spent on each major disease. Electronic supplementary material The online version of this article (doi:https ://doi.org/10.1007/s1019 8-018-0963-5) contains 
supplementary material, which is available to authorized users.
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Policy interventions that aim at improving population health 
require a thorough understanding of the importance of sin-
gle diseases and the evolution of disease-specific expendi-
tures over time. Disease-specific expenditures are important 
because they are likely to change with changes in access to 
care, medical progress, and increasing life expectancy.
A growing number of cost-of-illness studies have 
assessed the costs of single diseases in a variety of coun-
tries [1]. These studies usually cover only a fraction of the 
diseases affecting a country’s population, and they are often 
criticized for overestimating the true costs of diseases [2, 
3]. This overestimation may be due to methodological dif-
ficulties in isolating the expenditures for a specific disease 
in patients affected by multiple conditions. It may also be 
the consequence of an overestimation bias when researchers 
highlight the economic impact of the disease under study.
The aim of the present study was to decompose total 
healthcare spending in Switzerland in 2011 by disease and 
by other reasons for healthcare use. We applied a general 
cost-of-illness approach [3] assigning National Health 
Accounts (NHA) healthcare expenditures to a collec-
tively exhaustive and mutually exclusive set of diseases, 
thus avoiding double counting. NHA are published by the 
national statistical offices of many high-income countries 
and by the Swiss Federal Office of Statistics for Switzerland 
[4]. NHA assess the current level of healthcare expenditures 
and decompose them by type of financing source, financing 
regimen, service provider and service.
The System of Health Accounts 2011 that was coordi-
nated by OECD, Eurostat and WHO suggests a comprehen-
sive breakdown by disease [5]. A decomposition by diseases 
is, however, not part of the currently applied NHA standards. 
Nonetheless, healthcare expenditures have been partially 
decomposed by diseases for number of OECD countries 
including Australia, Canada, Korea, Japan and several Euro-
pean countries [6–8]. Furthermore, expenditures in numer-
ous low- and middle-income countries have been decom-
posed by the diseases of their key areas’ health burden, such 
as communicable diseases and conditions related to mater-
nal and child health [9]. However, the most comprehensive 
efforts to decompose spending by diseases have been carried 
in the USA. While some studies have focused on decom-
posing US healthcare spending by diseases [10, 11], others 
have focused on the impact on spending of potential driv-
ers, such as changes in cost per treated case or changes in 
treated prevalence [12–17]. To the best of our knowledge, 
the only study decomposing total spending by the same col-
lectively exhaustive set of disease classifications was the 
study by Dieleman and coauthors [11], which decomposed 
US personal healthcare spending (corresponding to 85% of 
the US’s NHA) into 155 diseases.
Our study may be interesting for health economists and 
public health researchers for a number of reasons: first, 
we combine a top-down approach, based on the disease 
information already contained in NHA, with a bottom-up 
approach based on patient-level microdata from a variety of 
sources. We perform a more detailed attribution of outpa-
tient spending than most previous studies. Our approach also 
differs to some extent from the one followed by Dieleman 
et al. [11] and may be applied to countries with less rich data 
on healthcare expenditures than the USA. Second, Swiss 
NHA are relatively complete and detailed in comparison 
with those of many other high-income countries [18]. Our 
study illustrates how this multidimensional measurement 
of healthcare expenditures can serve as a starting point for 
further enquiries into the drivers of healthcare spending. 
Third, our study illustrates how expenditures are allocated 
across diseases in a country with high healthcare spending, 
universal access to high-quality care and very little ration-
ing. Switzerland has one of the most expensive and gener-
ous healthcare systems with universal coverage and virtu-
ally no waiting time [19]. Per capita spending for health in 
Switzerland is among the highest in the world (USD 9813 
in 2015) and at a similar level as in the USA (USD 9892 in 
2016) [20].1 Even the purchasing power adjusted level of 
spending in Switzerland is approximately 30% higher than 
in European countries with similar healthcare systems such 
as Germany or the Netherlands [20]. Life expectancy is one 
of the highest in the world [22]; surveys report very high 
ratings of self-assessed health, and overall satisfaction with 
healthcare services is high [19].
Data and methods
We decomposed 2011 Swiss NHA healthcare expenditures 
by 21 major diseases. We first defined a collectively exhaus-
tive and mutually exclusive set of 21 diseases and 18 types 
of healthcare services and created a service–disease grid 
(described more thoroughly below) representing the over-
all envelope for the decomposition. Collectively, the cells 
of this grid aggregate to be 100% of NHA expenditures in 
Switzerland in 2011. Expenditures for each cell were esti-
mated by either a top-down or a bottom-up approach. The 
top-down approach estimated expenditures based on the 
information already contained in the NHA. The bottom-up 
approach assigned expenditures that could not be assigned 
by the top-down approach based on the analysis of micro-
data on healthcare utilization. These microdata contained 
1 Per capita spending was 9666 Swiss francs (CHF) in 2016 [20] 
with an exchange rate of 0.985 CHF/USD [21]. The share of health-
care spending in GDP was lower in Switzerland than in the US (12.4 
vs. 17.2%) [20] due to higher per capita income in Switzerland.
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additional information on both the types of diseases affecting 
individual patients and on related spending.
Classification of diseases and healthcare services
The first step was the identification of meaningful and appro-
priate categories of diseases and healthcare services at a 
suitable degree of granularity. A higher degree of granularity 
in the decomposition would not only allow for determining 
the spending for major disease groups, such as cardiovascu-
lar diseases, but also would allow for more specific sub-dis-
eases, such as ischemic heart disease. However, the details 
of the diagnostic information in the used data strongly lim-
ited the possible granularity of the decomposition. Only one 
data source included ICD-10 codes, and we had only limited 
access to patient-level data with partial diagnostic informa-
tion such as health insurance claims data. We thus chose 
the maximum achievable degree of granularity under the 
constraints of the available data and the financial resources 
for this study.
We adapted the disease classification used in the Global 
Burden of Disease Study (GBD) 2010 [23]. This study 
comprises three hierarchical classification levels, with 3 
disease groups at level 1, 21 disease groups at level 2, and 
291 diseases and injuries at level 3. The use of the GBD 
classification has several advantages: first, it represents a 
mutually exclusive and collectively exhaustive classification 
of all diseases and injuries. Second, it is used by the GBD-
Project to assess the country-specific incidence and preva-
lence of diseases as well as their health burdens in terms of 
disability-adjusted life years (DALYs). The GBD classifica-
tion thus allowed us to compare the healthcare spending for 
the treatment of diseases to the health burden in terms of 
DALYs of the same diseases. Third, the GBD classification 
was also used in a recent decomposition of US healthcare 
spending by disease [11], and the use of the same system 
allowed a comparison of the results.
We employed a modified version of the GBD level 2 clas-
sification (Table 1). The modifications included the addition 
of six disease categories within the non-communicable dis-
eases and the combination of all communicable diseases into 
one category. We also added two additional categories for 
well care and prevention, which are not included in the GBD 
classification because they do not represent a disease burden. 
Well care includes pregnancy and birth without substantial 
complications and other non-disease treatments by health-
care providers such as family planning or non-reconstructive 
cosmetic procedures. Prevention includes health promotion 
and disease and injury prevention programs financed by 
public and private organizations. It also includes disease 
Table 1  Classification by 21 diseases and other reasons for health service use Source: own adaptation of Global Burden of Disease Study (GBD) 
classification [23], with diseases ordered according to GBD
21 Major diseases Example Disease group on level 1 in GBD
Communicable diseases Lower respiratory infection Group 1: diseases dominating the 
burden of disease in low-income 
countries
Maternal and neonatal disorders Neonatal preterm complication
Nutritional deficiencies Iron-deficiency anemia
Neoplasms Lung cancer Group 2: non-communicable diseases
Cardiovascular diseases Ischemic heart disease
Chronic respiratory diseases Asthma
Cirrhosis and other chronic liver diseases Cirrhosis
Digestive diseases Gastritis
Neurological disorders (without dementia) Multiple sclerosis
Dementia Alzheimer’s disease
Mental and substance use disorders Depression
Urogenital, blood, and endocrine diseases (without 
diabetes)
Chronic kidney disease
Diabetes Diabetes mellitus
Musculoskeletal disorders Low back pain
Congenital anomalies Congenital heart anomaly
Skin diseases Acne
Sense organ diseases Hearing loss
Oral disorders Periodontal disease
Injuries Road injuries Group 3: injuries
Well care Pregnancy and birth without complications Not included in GBD classification
Prevention Accident prevention campaign
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prevention services delivered by healthcare providers such as 
vaccinations and screening examinations. Prevention spend-
ing is reported as a separate category because it would be 
very difficult to assign the spending for broad health promo-
tion to single diseases. Furthermore, Larg and Moss [24] 
have suggested separately reporting prevention spending in 
cost-of-illness studies. Table 1 gives an overview of the 21 
diseases and other reasons for health service use categories 
used in this study. For simplicity, we will refer to them as 
diseases emphasized in italics in the remainder of this text.
Healthcare services were classified using a slightly sim-
plified version of the Swiss NHA from the type of service 
perspective (Table 2) [4].2 The original type of service clas-
sification consisted of six main categories with 29 sub-cate-
gories. We omitted the sub-categories within prevention and 
administration and merged expenditures for drugs provided 
by pharmacies and by physicians into one category. Table 2 
illustrates the resulting collectively exhaustive and mutually 
exclusive classification of healthcare services with six main 
categories and 18 sub-categories.
The combination of 18 service categories and 21 disease 
categories resulted in a matrix of 378 service–disease cells. 
We pre-specified the row totals as the total spending for sin-
gle healthcare services according to NHA, which constitute 
a constraint to the decomposition. The column totals per dis-
ease were calculated after the assignment of service-specific 
NHA expenditures to different diseases. They represent the 
main result of our study.
Assigning expenditures to service–disease cells
We used either a top-down or a bottom-up approach to esti-
mate healthcare expenditures of each single service–disease 
cell. A number of cells were predefined as empty for certain 
diseases that should never require the use of certain health-
care services. Examples included prevention and well care, 
which should never require long-term nursing home care, or 
dental care, which should not be used for the treatment of 
cardiovascular or urogenital diseases.
Top‑down cells
The top-down approach made use of the available infor-
mation on disease-specific expenditures in the different 
Table 2  Classification of healthcare services Source: own elaboration based on [4]
a Expenditures include hoteling services for accommodations and food
b Mainly disabilities due to mental disorders, congenital birth defects and sense organ diseases
c Physicians may directly sell drugs to their patients in some Swiss cantons
6 Main categories 18 Sub-categories Notes
Inpatient  carea Acute inpatient care Acute care in hospitals and psychiatric clinics
Inpatient rehabilitation Rehabilitation in rehabilitation clinics
Inpatient long-term care Mainly nursing home care for the elderly
Other inpatient long-term Care in specialized institutions for disabled  patientsb
Outpatient care Outpatient physicians Primary care physicians and specialists
Outpatient hospital Care for patients without overnight stay
Outpatient dental care Care and prevention by dentists
Outpatient physiotherapy
Outpatient psychotherapy
Outpatient nursing Outpatient care for mainly elderly patients
Other paramedic services Including alternative medicine
Health products Drugs provided by  physiciansc and 
pharmacies
Prescription drugs, drugs provided by hospitals not included
Medical devices Devices provided directly to patients
Other outpatient services Clinical laboratory Only centralized laboratories outside hospitals
Radiology Only specialists and specialized outpatient centers
Ambulance and rescue
Prevention Prevention Tertiary prevention by government agencies
Administration Administration Public and private health insurers
2 Swiss NHA decompose health expenditures from four perspectives: 
(1) financing source, (2) financing regimen, (3) type of service pro-
vider, (4) type of service. In April 2017, the Swiss Federal Office of 
Statistics published a new version of NHA with a revised classifica-
tion within these perspectives [13]. Our study is based on the previ-
ously published version.
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dimensions of NHA. In the service-type dimension, the 
expenditures for psychotherapy and dental care were directly 
assigned to mental and substance use disorders and oral 
disorders. In the provider-type dimension, the expendi-
tures for psychiatric hospitals were assigned to mental and 
substance use disorders and dementia. The Swiss funding 
mechanisms further allowed for assigning expenditures by 
accident insurance companies that cover all residents in paid 
jobs to injuries, and assigning expenditures by the manda-
tory disability insurance that covers healthcare expenditures 
due to congenital birth defects until the age of 20 years to 
congenital anomalies.
All public health spending for prevention was assigned to 
the service–disease cell prevention—prevention.
Bottom‑up cells
The bottom-up approach used administrative data, insurance 
claims data, household survey data and physicians’ billing 
data to assign expenditures to the service–disease cells that 
could not be assigned by the top-down approach. We applied 
a hierarchical procedure based on the following principles:
1. Single service–disease cells were filled with information 
from a unique data source, except for the cells that could 
only partially be assigned with the top-down approach.
2. We started with the data of the highest quality and 
broadest coverage, and then gradually passed to less 
ideal data sources. For example, we used an inpatient 
episode registry instead of health insurance claims data 
to assign acute inpatient care expenditures to diseases, 
because the inpatient episode registry had a higher cov-
erage and more accurate diagnostic information. Con-
versely, we then used health insurance claims data as 
the preferred data source when assigning expenditures 
for hospital outpatient services to diseases.
The following section gives an overview of the proce-
dures that were followed in assigning expenditures to dis-
eases (see appendix for more details).
Inpatient care
Expenditures for inpatients in acute care hospitals, psychi-
atric clinics, rehabilitation clinics and nursing homes were 
assigned based on their main ICD-10 diagnoses coded in the 
Medical Statistic of Hospitals (MS). The MS is a registry 
of inpatient episodes by the Swiss Federal Office of Statis-
tics (FOS). It covers all inpatient stays uniquely identifying 
patients across multiple stays in different hospitals. The main 
diagnosis coded in the MS was particularly well suited for 
our analysis, as it corresponds to the diagnosis responsible 
for most of the resources used during an inpatient stay [25]. 
We used the 2011 MS containing 1,363,697 inpatient stay 
records (98.3% reported a diagnosis).
The procedures used to assign expenditures to single dis-
eases differed between inpatient care categories, because 
information on expenditures and diagnoses also differed 
between them.
Expenditures for acute care hospitals were assigned 
based on the main diagnosis and the AP-DRG3 cost weights 
assigned to each hospital stay in the MS. These expenditures 
were calculated as a product of number of stays assigned to a 
disease and the corresponding AP-DRG cost weights in 2011 
[26]. AP-DRG cost weights were missing for a relatively 
small number of stays (1.4%). Stays in psychiatric hospi-
tals or psychotherapeutic wards of acute care hospitals were 
assigned the average AP-DRG cost weight of the other stays 
in these wards. We then upscaled single acute care disease 
cells to match the NHA total for inpatient acute care by dis-
tributing residual expenditures proportionally to previously 
assigned acute care expenditures. This upscaling covered 
expenditure for yet unassigned stays and hospital investment 
expenditures not included in the AP-DRG cost weights, as 
well as additional charges for patients with private supple-
mentary health insurance.4
The proportion of total NHA expenditures for inpatient 
care by psychiatric hospitals was calculated by subtract-
ing the expenditures for outpatient services from the total 
expenditures for these hospitals. The resulting inpatient care 
expenditures for these hospitals were then assigned to men-
tal and substance use disorders and dementia proportionally 
to the total number of treatments days with these diagnoses 
in the MS.
The coding quality of MS records of rehabilitation clinics 
was often poor or missing. However, many stays in these 
clinics were preceded by treatments in acute care hospitals 
(more than 61% in the preceding 3-week period). We thus 
used the diseases coded as a patient’s main diagnosis in 
acute care hospitals to proportionally assign all rehabilita-
tion clinic stays to disease groups. Expenditures for inpatient 
rehabilitation were calculated by multiplying the average 
daily expenditures for rehabilitation clinics with the total 
number of treatment days in each disease group.
As we found no data directly assessing the diagnoses 
leading to long-term care in nursing homes, we used the 
information included in the MS to assign these expendi-
tures. We assessed the diagnoses of patients who were first 
referred to a nursing home after an inpatient stay in an acute 
3 AP-DRG was a prospective payment system (PPS) for acute care 
hospital stays used in the western and central cantons of Switzerland 
until 2011. In 2012, the new national SwissDRG PPS replaced it [9].
4 Private supplementary health insurance covers higher than standard 
hotel services and treatment by a head physician.
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care hospital. We did not assess the diagnoses of patients 
admitted to acute care from a nursing home, because these 
diagnoses might not be the cause of the first nursing home 
admission. As most patients in nursing homes were affected 
by multiple diseases, we identified the main diagnosis and 
the first two secondary diagnoses coded during the acute 
care episode before the first admission to the nursing home. 
All nursing home expenditures were then assigned propor-
tionally to the number of diagnoses assigned to each of the 
21 diseases.
Outpatient services and healthcare products
Expenditures for outpatient services and health prod-
ucts were assigned using a bottom-up approach based on 
microdata.
Attribution based on  claims data Some part of national 
expenditures for outpatient physicians and hospital care 
could be assigned to single service–disease cells based on 
claims data provided by the Helsana health insurance group. 
With over a million insured individuals, Helsana was one 
of the largest providers of mandatory health insurance in 
Switzerland and held a market share of 14% in 2011. Phar-
maceutical cost groups were used to identify seven non-
communicable diseases following the procedure described 
in Huber et al. [27]. The incremental expenditures associ-
ated with the identified diseases were estimated with a 
negative binomial regression with interaction terms. Total 
expenditures for each service–disease correspond to the 
product of incremental expenditures for a disease multiplied 
by its prevalence in the Helsana insurance population and 
then extrapolated to the overall population (see appendix for 
more details).
Attribution based on  the  Swiss Health Survey The 2012 
Swiss Health Survey (SHS) [28] allowed for assigning the 
expenditures for a number of outpatient service cells includ-
ing outpatient physician visits, physiotherapy, outpatient 
nursing and other outpatient services. The SHS is a repre-
sentative survey of the Swiss population aged 15 years and 
older living in private households. It assesses the service 
utilization of respondents with questions about the number 
of consultations of different healthcare providers in the pre-
vious 12 months. Respondents also reported on the diseases 
affecting them. We calculated disease-specific spending 
by combining the information on service use and diseases 
affecting the respondents (see appendix for more details).
Attribution‑based market research data We used market 
research data provided by IMS Health to assign the drug 
expenditures for a number of diseases. IMS Health pro-
vided contributions of these diseases to overall drug spend-
ing, based on information from pharmacies, physicians, 
drugstores and hospitals in 2011. Diseases were classi-
fied according to Anatomical Therapeutic Chemical Clas-
sification (ATC) codes that map drugs to different disease 
groups. Due to budget restrictions, we could obtain these 
drug expenditure data just for ten diseases (see appendix for 
more details).
Attribution based on  Medical Statistic of  Hospitals The 
MS holds information on whether a patient was admitted 
to inpatient care by ambulance. We used this information to 
assess the number of inpatient stays with ambulance admis-
sion in the 21 major disease categories. Overall spending for 
transport and rescue was then assigned to disease categories 
proportionally to the number of ambulance admissions.
Attribution based on  physicians’ billing data The NewIn-
dex physicians’ billing database allowed us to assign expen-
ditures to a number of additional service–disease cells. 
The database holds information on services and products, 
including drugs and laboratory tests, which were prescribed 
and provided in outpatient physician practices.
Expenditures could be mapped to diseases based on three 
types of information shown on physicians’ invoices. (1) The 
physicians’ specialization: expenditures related to a consul-
tation with an oncologist were, for example, assigned to 
neoplasms. (2) The type of insurance: expenditures covered 
by accident insurance related, for example, to injuries. (3) 
The Tessiner Code: a minimalist disease classification based 
on relatively broad diagnostic categories (such as diabetes) 
and localizations of the body parts affected (such as spine).
Attribution to remaining service–disease cells At this point 
of our procedure, a number of service–disease cells were 
still empty. Some of these cells were left empty while the 
remainder could be assigned to some of the yet unassigned 
spending.
Cells could be left empty for the following three reasons: 
(1) The service–disease cell was empty by definition, such 
as inpatient rehabilitation for the disease category prevention 
or the service dental care for dementia; (2) the row total of a 
service category had already been assigned to other disease 
cells in this row, and this was the case for other long-term 
care expenditures assigned entirely to five diseases; (3) there 
was a lack of diagnostic information in the microdata used 
for outpatient service attribution, such as for nutritional 
deficiencies and for cirrhosis or for the healthcare service 
category of radiology.
Regarding the service–disease cells that were assigned 
as part of the not yet assigned expenditures, we proceeded 
as follows: (1) missing expenditures for outpatient physi-
cians’ service–disease cells were assigned in proportion 
to the share of inpatient acute care expenditures for these 
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diseases; (2) missing expenditures for other outpatient ser-
vice–disease cells were assigned in proportion to outpatient 
physician services; (3) the administrative expenditures of 
health insurance companies were distributed in proportion 
to the total inpatient and outpatient cost already assigned to 
a disease.
Results
We decomposed overall Swiss healthcare expenditures by 
disease, with similar results so far available only for the USA 
[11]. The decomposition made use of diagnostic codes and 
clues contained in a multitude of data sources on healthcare 
expenditure and service use in Switzerland. We were able to 
assign the majority of spending to diseases.
Expenditures attributed with top‑down 
and bottom‑up approaches
The Swiss NHA reported healthcare spending of 64.6 bn 
Swiss francs (CHF)5 in 2011. Table 3 illustrates the assign-
ment of these expenditures to the predefined 378-cell ser-
vice–disease grid. A total of 75 cells were predefined as 
empty because the type of healthcare service did not fit 
with the type of disease. The top-down approach allowed 
for assigning 15.4% of total spending to 23 service–disease 
cells (mainly for mental and substance use disorders, con-
genital birth defects, injuries, and oral diseases).
The bottom-up approach assigned 75.2% of total spend-
ing to 170 service–disease cells based on the different data 
sources used:
• 38.6% based on MS hospital registry data (79 service–
disease cells for different types of inpatient care and 
ambulance services),
• 14.0% based on Helsana health insurance claims data 
(14 cells for physician and hospital services for selected 
non-communicable diseases),
• 7.9% based on IMS market research data (13 cells for 
drugs),
• 5.5% based on Swiss Health Survey data (14 cells, mainly 
for outpatient service categories other than physicians 
and hospital services),
• 5.2% based on NewIndex physicians’ billing data (31 
cells, mainly physician services not assigned with Hel-
sana data, drugs not assigned with IMS data and labora-
tory analysis across all disease categories).
• 4.0% based on the main type of disability affecting the 
patients living in other long-term care institutions (4 
cells). The remaining 15 cells for other long-term care 
remained empty.
At this stage of the procedure, 9.4% of total spending 
remained to be assigned. 5.5% was attributed to 98 empty 
service–disease cells mainly regarding outpatient physician 
services, radiology and medical devices. The remaining 
4.0% of spending comprised 18 health insurance adminis-
tration cells, which were assigned proportionally to health 
service spending for diseases.
Decomposition of expenditures by disease
The main result of our study is the decomposition of the 
2011 NHA expenditures by 21 major diseases. Table 4 pre-
sents these results in the 378 cell service–disease grid. The 
first three rows of the table show the total spending for each 
disease category in Swiss francs (CHF), the contribution 
of the disease to overall spending and the ranking of the 
diseases by share of expenditures. Figure 1 gives a visual 
overview of the relative contribution of diseases and disease 
groups to overall spending. The main results are summarized 
as follows:  
• Expenditures were dominated by non-communicable dis-
eases (79.4%), followed by injuries (8.1%), communica-
ble, maternal and nutritional diseases (6.4%), prevention 
(4.0%), and well care (2.4%).
• Cardiovascular diseases stood out as the most expensive 
disease category (15.6% of total spending), followed by 
musculoskeletal disorders (13.4%), mental and substance 
use disorders (10.6%), injuries (8.1%), and urogenital, 
blood and endocrine diseases (6.8%).
• Surprisingly, neoplasms ranked only sixth among the dis-
eases with the highest expenditures although neoplasms 
were a leading cause of premature death in Switzerland 
with 35.2% of years of life lost due to premature death in 
2010 [29].
• Prevention and well care, the two healthcare expenditure 
categories not related to the treatment of diseases, were 
responsible for 6.6% of spending (4.0% for prevention 
and 2.4% for well care).
• Six diseases accounted for less than 2.0% of healthcare 
spending. Surprisingly, they also included dementia 
(1.7% of total spending) and diabetes (1.5% of total), 
two chronic non-communicable diseases that are often 
referred to as important drivers for increasing healthcare 
spending [30–32].
The relative importance of various service categories dif-
fered considerably between diseases (Fig. 2). The proportion 
5 Average exchange rates in 2011 were 0.811 EUR/CHF and 1.127 
USD/CHF [21].
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Table 3  Overview of sources used to attribute expenditures in the service–disease grid
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Inpatient care
Acute care b b b b b b b b b ab abc b b b ab b b b b b v
Rehabilitation d d d d d d d d d d d d d d d d d d d v v
Long-term nursing b b b b b b b b b b b b b b b b b b b v v
Other long-term w w w w w w w w w w e w w e e w e w w v v
Outpatient care
Physicians g g x f f f x g g f f g f f a g g g a h h
Hospitals x x x f f f x x x f f x f f x x x x a x x
Dental care v v v v v v v v v v v v v v v v v a v v v
Physiotherapy x x x x h x x x x x h x x h a x x x a x v
Psychotherapy v v v v v v v v v v a v v v v v v v v v v
Outpatient nursing x x x h h x x x x x h x h h a x x x a v v
Other outpatient care x x x h x h x x x x h x x h a x x x a v v
Other services
Laboratory analysis g g x g g g x g g x g g g g a g g g ag g g
Radiology x x x x x x x x x x x x x x x x x x a x x
Transport and rescue i i i i i i i i i i i i i i i i i i ai i v
Sales of health goods
Drugs j g x j j j x j j j j j j j j j g g g g g
Medical devices x x x x x x x x x x x x x x a x x x a x v
Prevention v v v v v v v v v v v v v v v v v v v v a
Administration y y y y y y y y y y y y y y a y y v a y y
a NHA top-down
b MS main diagnosis + AP-DRG (somatic hospitals) or average daily rate (psychiatric clinics)
c MS average cost of psychiatric wards in somatic hospitals
d MS main diagnosis acute care + average daily rate for rehabilitation clinics
e Statistic of Socio-Medical Institutions (Somed)
f Helsana health insurance claims data
g NewIndex physicians' billing data
h Swiss Health Survey (SHS)
i MS information on admission via ambulance
j IMS Health market research data
v Empty by definition
w Empty because no expenditures
x Attribution of health services proportional to acute inpatient (for physicians) or physicians (for outpatient serv.)
y Attribution of insurance administration costs proportional to overall health service spending
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of inpatient care ranged from 0.0% in oral disorders to 
84.4% in maternal and neonatal disorders. Among the high-
expenditure disease groups, the proportion of inpatient 
care was particularly high for injuries (70.8%), neoplasms 
(63.8%) and mental disorders (59.3%). Outpatient care was 
particularly important in the treatment of oral disorders 
(99.1%), diabetes (57.1%), well care (52.2%), skin diseases 
(51.9%), and sense organ diseases (50.8%). The diseases 
with the highest proportion of outpatient drug and medical 
device expenditures were communicable diseases (23.9%), 
chronic respiratory diseases (27.2%), sense organ diseases 
(26.4%), skin diseases (23.3%) and diabetes (20.2%).
We also assessed the correlation between disease and 
service-specific healthcare expenditures and the two dimen-
sions of the health burden of diseases: years lived with dis-
ability (YLD) and years of life lost due to premature mor-
tality (YLL). Both YLDs and YLLs for Switzerland in the 
year 2010 were available from the GBD Study [23]. The 
correlation between spending and burden of disease was 
substantially stronger with YLDs (coefficient of 0.591) than 
with YLLs (coefficient of 0.404). The strongest correlation 
was between spending and DALYs, which equate to the sum 
of YLDs and YLLs (coefficient of 0.747).
Discussion
Our study is the first to decompose Swiss healthcare spend-
ing by major disease. We thus added a fifth dimension to 
Swiss NHA in addition to the four dimensions already pro-
vided by the FOS [4] (financing agent, financing regimen, 
type of service providers and type of service). The results 
showed that non-communicable diseases dominated health-
care spending in 2011 accounting for 79.4% of total spend-
ing. The five most costly non-communicable major diseases 
(cardiovascular, musculoskeletal, mental, urogenital and 
hematological, oral) accounted for over 50% of spending. 
Chronic diseases, such as musculoskeletal and mental disor-
ders, turned out to be more important drivers of healthcare 
spending than diseases associated with premature mortality 
such as neoplasms.
The methodological approach combined a top-down 
and a bottom-up approach, which allowed for assigning the 
Table 4  Decomposition of NHA expenditures by service and disease
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Total expenditures 64'633 3'037 701 237 3'880 10'084 1'632 196 3'018 1'309 1'077 6'861 4'387 990 8'662 2'968 1'199 1'096 3'965 5'216 1'526 2'592
  in percent of  total 100.0 4.7 1.1 0.4 6.0 15.6 2.5 0.3 4.7 2.0 1.7 10.6 6.8 1.5 13.4 4.6 1.9 1.7 6.1 8.1 2.4 4.0
  rank from largest 8 19 20 7 1 12 21 9 14 17 3 5 18 2 10 15 16 6 4 13 11
Inpatient care 29'188 1'497 563 169 2'355 4'218 526 89 1'643 753 765 3'868 1'957 214 3'727 2'145 282 237 1 3'569 609
   Acute care 16'847 873 548 32 1'724 2'314 341 54 1'181 296 298 2'537 912 74 2'156 628 163 134 1 1'973 609
   Rehabilitation 1'030 25 1 40 210 14 1 15 65 2 45 7 2 221 4 2 1 374
   Long-term nursing 8'604 600 15 136 591 1'695 170 34 447 392 465 328 1'039 138 1'123 43 116 52 0 1'221
   Other long-term 2'707 958 228 1'470 50
Outpatient care ** 21'501 549 69 35 644 3'882 539 60 679 361 187 1'560 1'314 470 3'747 248 548 501 3'921 941 733 513
   Phsysicians * 9'277 338 42 21 176 1'932 335 37 418 223 114 540 809 254 2'011 126 338 308 30 317 519 387
   Hospitals 5'380 110 14 7 398 1'272 104 12 136 72 38 652 263 146 1'114 41 110 100 10 489 168 126
   Dental care 3'873 3'873
   Physiotherapy 811 30 4 2 16 70 30 3 37 20 10 58 71 22 196 22 30 27 3 114 46
   Psychotherapy 220 220
   Outpatient nursing 1'734 64 8 4 54 568 64 7 80 42 22 72 154 43 414 1 64 59 6 9
   Other outpatient care 208 7 1 0 0 40 6 1 9 5 2 19 17 5 11 58 7 6 1 12
Other services 2'102 152 14 5 80 434 66 8 118 60 25 94 235 67 218 9 44 29 7 366 24 44
   Laboratory analysis 997 64 6 2 46 221 42 4 50 25 12 39 181 55 139 1 32 15 6 4 13 36
   Radiology 187 7 1 0 4 40 7 1 9 5 2 11 17 5 42 3 7 6 1 2 11 8
   Transport and rescue 918 80 8 3 30 173 17 4 59 31 11 44 37 6 37 5 5 7 0 359 1
Sales of health goods 7'360 690 21 17 610 1'056 422 29 430 70 48 1'002 665 190 547 263 266 275 36 164 85 473
   Drugs 6'079 650 16 14 590 827 382 24 381 44 34 938 570 160 309 40 226 239 32 104 24 473
   Medical devices 1'281 40 5 3 21 228 40 4 49 26 14 64 96 30 238 223 40 36 3 60 61
Prevention 1'434 1'434
Administration 3'048 149 34 12 190 494 80 10 148 64 53 336 215 48 424 302 59 54 177 75 127
National 
Health 
Accounts 
total W
el
l c
ar
e
Pr
ev
en
tio
n
Decomposition of 2011 Swiss National Health Accounts (NHA) in Swiss francs by disease. Empty cells hold no expenditures because the type 
of disease does not fit with the type of service or because no expenditures were assigned to these cells
*0.63% of spending for outpatient physicians’ spending was attributed proportionally to inpatient care spending
**The following shares of spending for services and health goods were assigned proportionally to outpatients physicians’ spending: 17.87% of 
outpatient care without physicians, 55.33% of other outpatient services and 14.08% of health goods
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Fig. 1  NHA expenditures by disease group and disease. The area of 
the boxes represents the share of a disease or disease group in total 
Swiss National Health Accounts expenditures in 2011. Exchange 
rates of Swiss franc (CHF) in 2011: 0.811 EUR/CHF, 1.127 USD/
CHF [21]. Non-communicable diseases (in blue) account for 79.4% 
of total spending
Fig. 2  Share of main service 
categories in disease expen-
ditures. Shares of expendi-
tures (net of health insurance 
administration costs) in disease 
expenditures. Diseases are 
ordered by the share of total 
inpatient spending (from highest 
to lowest)
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majority of service-specific expenditures to different disease 
categories. The accuracy of the assignment varied between 
service categories and largely depended on the availability 
of high-quality data. Diseases were identified by diagnostic 
codes of treatment episodes (e.g., ICD-10 codes in hospital 
registry data), by the type and specialization of service pro-
viders (e.g., psychiatric hospitals, dentist, oncologist, rheu-
matologist), and by the approved indications of drugs. In 
addition, attribution of spending to diseases was facilitated 
by two cause-specific social insurance schemes allowing for 
identifying spending for injuries (accident insurance) and 
congenital diseases (disability insurance) in NHA.
We are rather confident about the accuracy of our expend-
iture attribution for service–disease cells with high-quality 
information for disease identification. This confidence 
applies to most inpatient care cells and to outpatient-care 
cells representing high prevalence disease categories and 
major healthcare service categories. However, accuracy is 
poorer for low prevalence diseases and less central health-
care service categories, such as laboratory tests. Due to a 
lack of data, cirrhosis, nutritional deficiencies, physiother-
apy, outpatient nursing and radiology cells had to be filled 
according to the cells’ relative importance at the level of 
expenditures for outpatient physician services. The impact 
on the overall accuracy of the expenditure mapping of dis-
eases is nonetheless limited, as the subsequent assigned 
spending represented only 5.5% of total spending.
Our results can be interpreted as the direct expenditures 
for the treatment of a disease. The expenditures for the 
treatment of the comorbidities affecting a patient are thus 
only partially included in the expenditures for the primary 
disease. This is particularly true for expenditures assigned 
based on the type of financing regimen, the type of service, 
the specialization of the physician, or the ATC-code (for 
drug expenditures), as the underlying data sources allow 
for a precise separation of spending by disease. However, 
it is likely that some spending on comorbidities was also 
included in the inpatient acute care expenditures assigned 
to specific diseases, although the main diagnosis assigning 
expenditures to diseases was the diagnosis responsible for 
most of the costs. Spending on some comorbidities may also 
be included in the expenditures assigned with regression 
models, as these models could not control for all possible 
comorbidities.
Furthermore, the expenditures for the direct treatment of 
a disease differ from all the expenditures triggered by a dis-
ease. The case of diabetes may be useful in illustrating this 
point, as diabetes is an important risk factor for cardiovascu-
lar diseases, sense organ diseases and many other diseases. 
From an etiological perspective the expenditures for diabetes 
are likely to be much higher than our observed 1.5% of total 
healthcare expenditures, as a substantial part of the diseases 
induced by diabetes would be reallocated to diabetes. The 
case of osteoporosis (a musculoskeletal disorder) and falls 
(an injury) may further illustrate this point. Falls by elderly 
patients affected by osteoporosis often require intensive 
inpatient treatment. The corresponding healthcare spending 
would appear among the injuries in our classification, while 
they would be assigned at least partially to musculoskeletal 
disorders from an etiological perspective.
Our results are in line with the decomposition of US per-
sonal healthcare spending in Dieleman et al. [11] and in 
Roehrig et al. [10]. The ranking and scale of spending for 
major diseases determined in these studies are similar to 
our results for Switzerland. Conversely, our results diverge 
somewhat from those of Dunn and coauthors [15, 16], based 
on the Health Care Satellite Account developed by the US 
Bureau of Economic Analysis. These differences are in part 
due to differences in the disease classification. The second 
most important spending category in Dunn et al. [15] is for 
example “Routine care, signs and symptoms” (12.4% of 
spending), which does not appear in the GBD classification 
applied Dieleman et al. [11] and our study. A comparison 
with the results of Heijink and coauthors [6] for Australia, 
Canada, France, Germany and the Netherlands and with 
more recent findings for a number of OECD countries [8] 
shows larger differences with our results. However, these 
differences may be largely attributable to the methodological 
limits of the spending decompositions for these countries, 
such as the allocation of only a part of total spending to 
diseases [6].
The results of our study may be useful to researchers and 
health policy makers in several ways: first, better knowledge 
of the distribution of overall healthcare spending across dis-
eases may contribute to more efficient priority setting for 
health policies and budgetary planning. If life expectancy 
is continuing to increase and medical progress transforms 
more lethal diseases into chronic ones, then spending for 
high prevalence chronic diseases is expected to grow dis-
proportionally. Second, the results provide an overall refer-
ence for single cost-of-illness studies. This reference may 
be useful to verify the plausibility of single cost-of-illness 
studies, and thus helps to prevent misallocations of resources 
because of the risk of overestimation and double counting 
in single cost-of-illness studies [2]. Third, our study illus-
trates how healthcare spending can be assigned to single 
diseases when no diagnostic information is available. This 
may be useful for the decomposition of healthcare spending 
in countries with limited diagnostic information in expendi-
ture or service use data. Fourth, our results may serve as an 
input for studies assessing the healthcare costs attributable 
to behavioral or environmental risk factors such as smoking 
or air pollution. Such studies typically assess the fractions of 
disease prevalence or incidence attributable to a risk factor 
of interest. These attributable fractions are then multiplied 
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with the healthcare spending for single diseases to calculate 
the spending attributable to the risk factor.
Our study has a number of limitations. First, our analyti-
cal options were restricted by the limited access to health 
insurance claims data. Broader access to such data would 
have allowed for a substantially better attribution of expendi-
tures to service–disease cells related to minor outpatient ser-
vices and relatively low disease prevalence. However, these 
restrictions were mainly due to limited resources available 
and could be overcome in future estimations. Second, due to 
a lack of suitable data, the expenditures related to a number 
of service–disease cells had to be attributed proportionally 
to previously assigned cells. However, the consequences on 
overall results are likely to be limited as only 5.5% of the 
total spending was assigned proportionally. Third, the accu-
racy of the attribution of expenditures differs substantially 
between disease and service categories. While accuracy is 
higher for inpatient acute care and outpatient physician and 
hospital services, it is lower for long-term inpatient care 
and minor outpatient services. Thus, there is much room 
for the use of better data and the development of improved 
methods for the cost attribution. Fourth, with our approach, 
the granularity of the decomposition is often limited to a 
decomposition by main disease groups. The expenditures 
for the disease category neoplasms can, for example, not 
be decomposed by different types of neoplasms based on 
the physicians’ specialization or types of drugs, as oncolo-
gists may treat patients affected by different types of neo-
plasms and many drugs are used to treat different forms of 
neoplasms. More detailed diagnostic coding would thus be 
required for decomposition with higher granularity.
Further research may include the decomposition of dis-
ease-specific spending by age, gender and type of payer. Bet-
ter access to health insurance claims data may also allow for 
higher granularity in disease decomposition, particularly for 
the high-expenditure cardiovascular diseases, musculoskel-
etal disorders and mental and substance use disorders. Our 
study may also serve as a starting point for further research 
into the drivers of the constant growth of healthcare spend-
ing. To this end, disease-specific spending must be assessed 
in different years. The changes in spending over time could 
then be decomposed into changes in the age structure and 
size of the population, in the prevalence of diseases, in the 
access-to-care restrictions, in the intensity and type of care, 
and in the prices of healthcare services and products.
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